Across randomized cardiovascular outcome trials and meta-analyses, SGLT2 inhibitors consistently reduce hospitalization for heart failure by approximately 3037% (hazard ratio [HR] 0.630.70), with benefits observed regardless of prior atherosclerotic cardiovascular disease status [6, 23]
Cobalamin [Cbl(I)] initially provides two electrons to the catalytic cycle, enabling the energy-dependent transfer of a methyl group from MTHF to Hcy
Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, et al
Consistency is key for best results
Mice were fasted for 5 hours followed by administration of 1.5 g/kg glucose for an oral glucose tolerance test (OGTT)
Bush JR, Wevrick R